20cm速递 | 创业板医药ETF国泰（159377）盘中涨超3.0%，政策红利或助推细分领域估值修复

Group 1 - The National Healthcare Security Administration has issued the "Interim Measures for Payment Management by Disease," promoting payment reform and clarifying total budget management, grouping adjustment cycles, and payment standard calculations [1] - The preliminary list of innovative drugs for medical insurance and commercial insurance for 2025 has been published, with several cancer drugs (such as bispecific antibodies, CAR-T therapies, and ADCs) and new chronic disease drugs passing the review, indicating potential rapid market release for these innovative drugs [1] - Semaglutide has received FDA approval for the treatment of metabolic dysfunction-associated fatty liver disease (MAFLD), further expanding the application scenarios for GLP-1 drugs [1] Group 2 - The Guotai Junan Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which can experience daily fluctuations of up to 20%. This index selects listed companies engaged in biotechnology, innovative pharmaceuticals, and medical services from the ChiNext market, focusing on companies with core R&D capabilities and high growth characteristics [1]